BURLINGAME, Calif. (AP) _ Kindred Biosciences Inc. (KIN) on Thursday reported a loss of $14.3 million in its second quarter.
The Burlingame, California-based company said it had a loss of 37 cents per share.
The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 36 cents per share.
The biopharmaceutical company posted revenue of $1.2 million in the period, which also fell short of Street forecasts. Three analysts surveyed by Zacks expected $2 million.
Kindred Bio shares have declined 36% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $6.96, a decrease of 49% in the last 12 months.